Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...

What’s more, AM-101 improved radiation treatment, slowing down the growth of NSCLC subcutaneous xenograft tumors in mice, by ...

In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...

The American College of Radiology advises women who are at average risk for breast cancer to get mammograms annually starting ...

Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...

For the first time, the National Institute for Health and Care Excellence has recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...

Novocure GmbH secured U.S. FDA approval for Optune Lua, a wearable device that delivers alternating electric fields or tumor treating fields that kill cancer cells. Indicated for use with PD-1/PD-L1 ...

Novocure stock rocketed late Tuesday after the FDA signed off on its treatment for patients with metastatic lung cancer.

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.